Lovastatin and tumor necrosis factor-α exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor- induced angiogenesis

International Journal of Cancer

Volumn 81, Issue 4, 1999, Pages 560-567

  Feleszko, Wojciech ^a,b   BaŁkowiec, Ewa Z ^a   Sieberth, Elisabeth ^a,c   Marczak, Maria ^b   Dabrowska, Anna ^a   Giermasz, Adam ^a   Czajka, Anna ^a   Jakóbisiak, Marek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MEVINOLIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN 3T3; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIAL GROWTH FACTORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; LOVASTATIN; LYMPHOKINES; MACROPHAGES; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0344948143     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990517)81:4<560::AID-IJC10>3.0.CO;2-7     Document Type: Article

References (25)

1. ALBERTS, A.W., Discovery, biochemistry and biology of lovastatin. Amer. J. Cardiol., 62, 10J-15J (1988).
2. BARBACID, M., ras genes. Ann. Rev. Biochem., 56, 779-827 (1987).
3. CORBETT, T., VALERIOTE, F., LORUSSO, P., POLIN, L., PANCHAPOR, C., PUGH, S., DEMCHIK, L., JONES, J. and LISOW, L., In vivo methods for screening and preclinical testing. In: B. Teicher (ed.), Anticancer drug development guide: preclinical screening, clinical trials, and approval, pp. 75-99, Humana Press, Totowa, NJ (1997).
4. DECLUE, J.E., VASS, W.C., PAPAGEORGE, A.G., LOWY, D.R. and WILLUMSEN, B.M., Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res., 51, 712-717 (1991).
5. FELESZKO, W., LASEK, W., GOŁA̧B, J. and JAKÓBISIAK, M., Synergistic antitumor activity of tumor necrosis factor-α and lovastatin against MmB16 melanoma in mice. Neoplasma, 42, 69-73 (1995).
6. FELESZKO, W., ZAGOŻDŻON, R., GOŁA̧B, J. and JAKÓBISIAK, M., Potentiated antitumor effects of cisplatin and lovastatin against MmB16 melanoma in mice. Europ. J. Cancer, 34, 407-411 (1998).
7. HORI, K., EHRKE, M.J., MACE, K. and MIHICH, E., Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and γ-interferon. Cancer Res., 47, 5868-5874 (1987).
8. JAKÓBISIAK, M., BRUNO, S., SKIERSKI, J.S. and DARZYNKIEWICZ, Z., Cell cycle-specific effects of lovastatin. Proc. nat. Acad. Sci. (Wash.), 88, 3628-3632 (1991).
9. KOMORI, A., YATSUNAMI, J., SUGANUMA, M., OKABE, S., ABE, S., SAKAI, A., SASAKI, K. and FUJIKI, H., Tumor necrosis factor acts as tumor promoter in BALB/3T3 cell transformation. Cancer Res., 53, 1982-1985 (1993).
10. KORMAN, L. and BORYSIUK, L., Replacing lovastatin with pravastatin: effect on serum lipids and costs. Amer. J. Health-Syst. Pharm., 52, 1078-1082 (1995).
11. LASEK, W., FELESZKO, W., GOŁA̧B, J., STOKŁOSA, T., MARCZAK, M., DA̧BROWSKA, A., MALEJCZYK, M. and JAKÓBISIAK, M., Antitumor effects of the combination immunotherapy with IL-12 and TNF-α in mice. Cancer Immunol. Immunother., 45, 100-108 (1997).
12. LEBEAU, J., LE CHALONY, C., PROSPERI, M.T. and GOUBIN, G., Constitutive overexpression of a 89 kDa heat shock protein gene in the HBL100 human mammary cell line converted to a tumorigenic phenotype by the EJ/T24 Harvey-ras oncogene. Oncogene, 6, 1125-1132 (1991).
13. MANDA, T., SHIMOMURA, K., MUKUMOTO, S., KOBAYASHI, K., MIZOTA, T., HIRAI, O., MATSUMOTO, S., OKU, T., NISHIGAKI, F., MORI, J. and KIKUCHI, H., Recombinant human tumor necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res., 47, 3707-3711 (1987).
14. MANO-HIRANO, Y., SATO, N., SAWASAKI, Y., HARANAKA, K., SATOMI, N., NARIUCHI, H. and GOTO, T., Inhibition of tumor-induced migration of bovine capillary endothelial cell by mouse and rabbit tumor necrosis factor. J. nat. Cancer Inst., 78, 115-120 (1987).
15. MARUTA, H., HOLDEN, J., SIZELAND, A. and D'ABACO, G., The residues of Ras and Rap proteins that determine their GAP specificities. J. biol. Chem., 226, 11661-11668 (1991).
16. RAK, J., MITSUHASHI, Y., BAYKO, L., FILMUS, J., SHIRASAWA, S., SASAZUKI, T. and KERBEL, R.S., Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55, 4575-4580 (1995).
17. RUCH, R.J. and SIGLER, K., Growth inhibition of rat liver epithelial tumor cells by monoterpenes does not involve Ras plasma membrane association. Carcinogenesis, 15, 787-789 (1994).
18. RUGGIERO, V., LATHAM, K. and BAGLIONI, C., Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J. Immunol., 138, 2711-2717 (1987).
19. SATO, N., GOTO, T., HARANAKA, K., SATOMI, N., NARIUCHI, H., HIRANO, Y. and SAWASAKI, Y., Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J. nat. Cancer Inst., 76, 1113-1121 (1986).
20. SHIMOMURA, K., MANDA, T., MAKUMOTO, S., KOBAYASHI, K., NAKANO, K. and MORI, J., Recombinant human tumor necrosis factor-α: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer, 41, 243-247 (1988).
21. SUMI, S., BEAUCHAMP, D., TOWNSEND, C.M., UCHIDA, T., MURAKAMI, M., RAJARAMAN, S., ISHIZUKA, J. and THOMPSON, J.C., Inhibition of pancreatic adenocarcinoma cell growth with lovastatin. Gastroenterology, 103, 982-989 (1992).
22. TAMANOI, F., Inhibitors of Ras farnesyltransferases. Trends biochem. Sci., 18, 349-353 (1993).
23. THIBAULT, A., SAMID, D., TOMPKINS, A.C., FIGG, W.D., COOPER, M.R., HOHL, R.J., TREPEL, J., LIANG, B., PATRONAS, N., VENZON, D.J., REED, E. and MYERS, C.E., Phase I study of lovastatin, an inhibitor of the mevalonate pathway in patients with cancer. Clin. Cancer Res., 2, 483-491 (1996).
24. WEBER, C., ERL, W. and WEBER, P.C., Lovastatin induces differentiation of Mono Mac 6 cells. Cell. Biochem. Funct., 13, 273-277 (1995).
25. WILLUMSEN, B.M., CHRISTENSEN, A., HUBBERT, N.L., PAPAGEORGE, A.G. and LOWY, D.R., The p21ras C terminus is required for transformation and membrane association. Nature (Lond.), 310, 583-586 (1984).